Who We Are
CDG Therapeutics Inc. was founded at the University of Illinois, Chicago College of Medicine By Drs AM Chakrabarty, Ph.D. and Tapas K. Das Gupta, M.D., Ph.D., D.Sc, and incorporated in the State of Delaware in May 2001, following the discovery that peptides derived from the cupredoxin family of bacterial and plant proteins preferentially penetrate cancer cells and exert novel therapeutic activities. As a founder and Chairman Emeritus of CDG, Dr. Das Gupta continues to serve as the guiding light in clinical and basic science research and development.
CDG holds the exclusive worldwide license with commercialization rights on the cell-penetrating peptides (CPPs) derived from the cupredoxin family of redox proteins as well those derived from additional infectious bacteria. It remains affiliated with the University of Illinois though Sponsored Research Agreement and is seeking strategic partnership(s) and additional capital to conduct Phase II clinical trials in advanced, refractory, adult and pediatric CNS tumors and prostate cancer.
The company’s research and development is currently funded through private equity investments and research grants.